Niagen Bioscience (NAGE) 2nd Annual Lytham Partners Healthcare Investor Summit summary

Company overview and product focus

• Niagen Bioscience, formerly ChromaDex, specializes in nicotinamide riboside (NR), branded as Niagen, a leading NAD precursor with over 100 patents and extensive clinical validation.

• NAD is vital for cellular energy and repair; elevating NAD with Niagen supports resilience against aging and stress-related conditions.

• Niagen is offered as a dietary supplement, B2B ingredient, and now as IV/injection, with both food-grade and pharmaceutical-grade options.

• The company is net income and cash flow positive, with no debt and a strong, diversified business model.

• Tru Niagen is a top-selling supplement in the U.S. and internationally, with growing injectable and IV offerings.

Scientific research and competitive differentiation

• Over 41 clinical and 100 preclinical studies published on Niagen, with unmatched R&D investment in the NAD supplement space.

• Niagen elevates NAD more efficiently and safely than NAD or NMN supplements, with a natural cellular uptake pathway.

• The ChromaDex External Research Program (CERP) has over 300 collaborations with leading institutions, generating significant IP.

• The company’s science-driven approach is supported by a network of top global researchers and ongoing patent development.

Business expansion and future plans

• Niagen Plus B2B business supplies compound pharmacies for IV/injection products, with a direct-to-consumer telehealth launch planned within six months.

• Plans to offer home injection kits and partner with telehealth companies selling similar products, targeting the growing self-injection trend.

• Pharmaceutical applications are being pursued, focusing on orphan diseases like Ataxia-telangiectasia, with promising early clinical results.

• Skincare is identified as a major future vertical, with aggressive expansion and announcements expected in 2026.